Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Fletcher

Showing results (271-280 of 326) with videos related to

Pageof 33
Sort By:
The Journal of Antimicrobial Chemotherapy|February 20, 2016
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)Jose R Castillo-Mancilla, Christina L Aquilante, Michael F Wempe, et al.
Current Protocols|June 10, 2024
Establishment of a Four-Cell In Vitro Blood-Brain Barrier Model With Human Primary Brain CellsJohid R Malik, Ukamaka O Modebelu, Courtney V Fletcher, et al.
The Journal of Infectious Diseases|February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesTimothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2022
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapyShadia Nakalema, Catherine A Chappell, Michelle Pham, et al.
The Journal of Infectious Diseases|February 1, 1997
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study GroupJ S Lambert, L M Mofenson, C V Fletcher, et al.
The Journal of Infectious Diseases|March 13, 2018
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ARTMonica Gandhi, Rajesh T Gandhi, Andrei Stefanescu, et al.
Neuro-Oncology Advances|December 11, 2024
Ion channel modulator DPI-201-106 significantly enhances antitumor activity of DNA damage response inhibitors in glioblastomaBrittany Dewdney, Panimaya Jeffreena Miranda, Mani Kuchibhotla, et al.
Antiviral Research|April 10, 2018
Adipocytes impair efficacy of antiretroviral therapyJacob Couturier, Lee C Winchester, James W Suliburk, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissuesCourtney V Fletcher, Kathryn Staskus, Stephen W Wietgrefe, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasmaD W Haas, L A Clough, B W Johnson, et al.
Pageof 33

Showing results (271-280 of 326) with videos related to

Sort By:
Pageof 33
The Journal of Antimicrobial Chemotherapy|February 20, 2016
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)Jose R Castillo-Mancilla, Christina L Aquilante, Michael F Wempe, et al.
Current Protocols|June 10, 2024
Establishment of a Four-Cell In Vitro Blood-Brain Barrier Model With Human Primary Brain CellsJohid R Malik, Ukamaka O Modebelu, Courtney V Fletcher, et al.
The Journal of Infectious Diseases|February 5, 2009
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesTimothy J Wilkin, John E McKinnon, A Gregory DiRienzo, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2022
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapyShadia Nakalema, Catherine A Chappell, Michelle Pham, et al.
The Journal of Infectious Diseases|February 1, 1997
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study GroupJ S Lambert, L M Mofenson, C V Fletcher, et al.
The Journal of Infectious Diseases|March 13, 2018
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ARTMonica Gandhi, Rajesh T Gandhi, Andrei Stefanescu, et al.
Neuro-Oncology Advances|December 11, 2024
Ion channel modulator DPI-201-106 significantly enhances antitumor activity of DNA damage response inhibitors in glioblastomaBrittany Dewdney, Panimaya Jeffreena Miranda, Mani Kuchibhotla, et al.
Antiviral Research|April 10, 2018
Adipocytes impair efficacy of antiretroviral therapyJacob Couturier, Lee C Winchester, James W Suliburk, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissuesCourtney V Fletcher, Kathryn Staskus, Stephen W Wietgrefe, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasmaD W Haas, L A Clough, B W Johnson, et al.
Pageof 33